RETand HSCR Flashcards

1
Q

What is Harald Hirschsprung
(1830-1916) famous for?

A

Constipation associated with dilation and hypertrophy of the colon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe Hirschsprung’s Disease (HSCR)

A
  • HSCR is characterized by the ABSENCE of enteric ganglia belonging to the hindgut. Usually the abnormalities are restricted to the last few centimeters of the distal colon, but they can extend to the proximal colon or the distal small intestine.
  • The aganglionic gut is tonically contracted. Symptoms range from life threatening total obstruction to chronic constipation or fecal incontinence.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe enteric ganglia distribution

A

The enteric ganglia are distributed throughout the gut wall 500 million neurons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

TRUE or FALSE: Both the submucosal and myenteric ganglia
are missing in HSCR

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What was the first clue that RET was involved in HSCR?

A
  • The neuronal phenotype of RET-/- mice resembles that of humans suffering HSCR.
  • The phenotype also resembles that of mice lacking GDNF and mice lacking GFRa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

RET -/- Mice

A

1) Die soon after birth
2) Lack enteric neurons throughout the digestive

tract

3) Abnormal kidney development

(A study of human stillborn foetuses in which the kidneys

failed to form showed an association with RET mutations)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The Genetics of RET in HSCR

A
  • At least 24 different genes have been strongly associated with HSCR
  • Heterozygous germline mutations in RET account for 50%of familial HSCR patients (about 20% of sporadic).
  • Functional loss of a single copy of the gene is sufficient tocause pathology in some patients suffering from HSCR.(inheritance is dominant but shows incomplete penetrance).
  • A large number of “gene modifiers” contribute to the severity/lack of severity of the phenotype.
  • Gene modifiers include the genes for the neuropeptide endothelin-3 (ET-3) and its G-protein coupled receptor, endothelin receptor (EDNRB) as well as non-coding single nucleotidepolymorphism variants in the vicinity of RET and SEMA3 (semaphorin 3).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

A FAMILY WITH HSCR

A

All subjects with HSCR carry the m (mutant) allele

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Interpretation of Affected Heterozygotes

A
  • Two wild-type copies of RET may be required for normal RET function. Therefore receptor number or amount of signal is crucial for at least some RET functions.
  • You can’t always get by with one good allele
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

RET mutations in HSCR

A
  • Deletions of the whole gene Intragenic deletions and insertions Nonsense mutations (also called STOP/GAIN) Splicing errors
  • Missense mutations throughout the coding region
  • SNPs in non-coding regions (promoters and introns) which decrease expression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

The Location of the HSCR Mutation Determines the
Functional Consequence of the Mutation

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why do we get MEN2A and HSCR in the same patient?

A
  • Constitutively active receptors that don’t bind ligand may not signal strongly enough in the enteric neurons.
  • Mutations in RET which cause constitutive activation often reduce the expression of RET at the plasma Membrane.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe RET Expression in Normal Mouse Development

A

1) Central nervous system (motor and catecholaminergic neurons)
2) Cells of the peripheral nervous system

derived from the neural crest including sensory, autonomic, and enteric ganglia

3) C cells of the thyroid
4) Kidney organogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

RET is Expressed in Cells Derived from the
Neural Crest including the enteric ganglia

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is GDNF (Glial Derived Neurotrophic Factor?

A
  • GDNF was discovered in the search for factors that promote the survival of midbrain dopaminergic neurons, in the hopes of finding a treatment for Parkinsons
  • GDNF supports the survival in vitro of sensory, sympathetic, and motor neurons
  • In vitro GDNF is a potent chemotrophic, mitogenic and trophic factor for neural-crest-derived enteric progenitors

(progenitors can both divide and give rise to cells which differentiate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe RET and GDNF in the Enteric Nervous System

A
  • Vagal neural crest cells (NCC—shown as neuroblast) express RET and GFRa1 during their migration through the intestinal mesenchyme and subsequently in the myenteric and submucosal plexuses. Most ENS progenitors are Vagal NCC.
  • GDNF is expressed in the mesenchyme of the gut wall.
17
Q

Migration of NCC in the Gut

A

Enteric Nervous System progenitors originate in the Vagal neural crest (NC).

The NCC migrate through the foregut and midgut to reach the hindgut. In a mouse, the process takes several days.

18
Q

Evidence that NCC Migrating through the Gut Express RET

A
  • NCC migration in transgenic mice in which one allele of RET is driving GFP. (confocal microscopy of a whole mount)
  • Phox2b is a transcription factor expressed in NCC
19
Q

Migration of NCC

A

Explants of E12.5 hindgut in the mouse. Time Lapse of GFP-labelled NCC.

20
Q

Timing of NCC Migration in the Gut

A
  • In humans, NCC enter the foregut during the 4th week of gestation.
  • When the NCC enter the foregut, they rapidly proliferate
  • By week 7.5, they have reached the hindgut.
21
Q

Hypothesis

A
  • The absence of enteric neurons in HSCR patients with mutations in RET results from the failure of neural crest cells destined for the gut to survive, proliferate, migrate, or differentiate.
  • There is evidence to support all of these.
22
Q
A
23
Q

Describe current and future therapies

A
  • Current Therapy: Surgery to remove aganglionic bowel
  • Refractory constipation and fecal incontinence affecting between 10% and 30% of patients,
  • Future Therapy: Stem cell replacement of missing neurons
24
Q

Proposed Steps involved in Stem Cell Therapy for HSCR

A
25
Q

Alternate Approach: IPSC and CRISPR/CAS9

A

Correction of Hirschsprung-Associated Mutations in HumanInduced Pluripotent Stem Cells Via Clustered RegularlyInterspaced Short Palindromic Repeats/Cas9, RestoresNeural Crest Cell